Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 06, 2020 07:00 ET | Source: Brickell Biotech, Inc.

Brickell Biotech Announces Initiation of U.S. Phase 3 Program Evaluating Sofpironium Bromide Gel, 15% for the Treatment of Primary Axillary Hyperhidrosis

Primary axillary hyperhidrosis is estimated to affect over 10 million people in the U.S. Sofpironium bromide is a retrometabolically designed investigational new chemical entity BOULDER,...
September 25, 2020 07:00 ET | Source: Brickell Biotech, Inc.

Brickell Biotech Announces Approval of Sofpironium Bromide Gel, 5% in Japan for Treatment of Primary Axillary Hyperhidrosis Received by its Development Partner, Kaken Pharmaceutical

Japan is the first country to approve sofpironium bromide with commercial launch expected later this year Brickell is on track to initiate its U.S. pivotal Phase 3 program for sofpironium bromide in...
September 10, 2020 16:05 ET | Source: Brickell Biotech, Inc.

Brickell Biotech to Participate in September Virtual Investor Conferences

BOULDER, Colo., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated...
September 08, 2020 07:30 ET | Source: Brickell Biotech, Inc.

AnGes and Brickell Biotech Announce a Collaboration Agreement for the Development of a Novel DNA Vaccine Candidate for COVID-19 in the U.S.

IBARAKI CITY, Osaka and BOULDER, Colo., Sept. 08, 2020 (GLOBE NEWSWIRE) -- AnGes, Inc. (“AnGes”), announced today a collaboration agreement with Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a...
August 31, 2020 16:05 ET | Source: Brickell Biotech, Inc.

Brickell Biotech Announces Issuance of New Composition of Matter Patent on Sofpironium Bromide by the Japanese Patent Office

Claims directed to novel crystalline forms of sofpironium bromide Patent protection in Japan granted through 2040 BOULDER, Colo., Aug. 31, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc....
August 12, 2020 16:01 ET | Source: Brickell Biotech, Inc.

Brickell Biotech Reports Second Quarter 2020 Financial Results and Provides Corporate Update

Positive data from the Sofpironium Bromide Phase 3 pivotal study in Japan presented in Q2 2020 by development partner, Kaken Kaken to receive regulatory decision in Japan for sofpironium bromide gel...
August 03, 2020 16:05 ET | Source: Brickell Biotech, Inc.

Brickell Biotech to Report Second Quarter 2020 Financial Results and Provide a Corporate Update on August 12, 2020

BOULDER, Colo., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated...
June 17, 2020 22:00 ET | Source: Brickell Biotech, Inc.

Brickell Biotech, Inc. Announces Pricing of $20.1 Million Underwritten Public Offering

BOULDER, Colo., June 17, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated...
June 15, 2020 06:30 ET | Source: Brickell Biotech, Inc.

Brickell Biotech Announces Positive Phase 3 Pivotal Study Results for Sofpironium Bromide in Japan Released by Development Partner, Kaken Pharmaceutical

Data based on registration study in Japan of sofpironium bromide gel, 5% in patients with primary axillary hyperhidrosis All primary and secondary endpoints were met and achieved statistical...
May 13, 2020 16:01 ET | Source: Brickell Biotech, Inc.

Brickell Biotech Reports First Quarter 2020 Financial Results and Provides Corporate Update

BOULDER, Colo., May 13, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated...